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Background: Previous studies have been inconsistent with respect to the reported associations between human
epidermal growth factor receptor (HER-2/neu) overexpression in colorectal cancer. The aims of this meta-analysis
are to assess its correlation with clinicopathological characteristics and prognostic significance in colorectal cancer.
Methods: Eligible studies were searched in Pubmed, Embase and Web of Science databases. The inclusion criteria
were studies that assessed the relationship between HER-2 expression detected by immunohistochemistry (IHC)
and the prognosis or clinicopathological features in patients with colorectal cancer (CRC). Subgroup analysis
according to sex, tumor location, TNM stage, grade of differentiation and lymph node metastasis were produced.
Odds ratio (OR) or hazard ratio (HR) with 95 % confidence interval (CI) were calculated to examine the risk or
hazard association, and heterogeneity and publication bias analyses were also performed.
Results: A total of 18 studies comprising 2867 colorectal cancer patients were included to assess the association
between HER-2 immunohistochemical expression and clinicopathological characteristics and survival. The overall
analysis showed that there was no detectable relation between HER-2 expression and prognosis in colorectal cancer
patients with the pooled HR of 1.08 (95 % CI: 0.96–1.21, P = 0.21). With respect to clinicopathological features, there was
also no detectable relation between HER-2 expression and sex (OR = 0.91, 95 % CI: 0.72–1.15, P = 0.42), tumor location
(OR = 1.21, 95 % CI = 0.88–1.65, P = 0.24), grade of differentiation (OR = 1.03, 95 % CI = 0.72–1.47, P = 0.86), TNM stages
(OR = 0.72, 95 % CI = 0.31–1.66, P = 0.44), or lymph node metastasis (OR = 1.90, 95 % CI = 0.90–4.02, P = 0.09) in CRC.
Conclusions: The finding from this present meta-analysis suggested that HER-2 overexpression was not related to
clinicopathological characteristics and poor prognostic of colorectal cancer patients.Background
Despite the clinical prognosis for colorectal cancer has been
improved by the development of surgery and adjuvant
chemoradiotherapy, the long-term survival of colorectal
cancer patients is highly unsatisfactory and hindered by
recurrence and distant metastasis [1]. The prognostic
factors that have been implicated include demographics,
tumor size, tumor site, stage, and response to chemother-
apy. However, the mechanism of prognosis in colorectal* Correspondence: surgeonchen_1@163.com
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article, unless otherwise stated.cancer patients is still not fully understood. Therefore, a
better understanding into its basic biology is urgently
needed to identify its prognostic markers and therapeutic
targets. Much effort has been made for a long time to
identify an established marker possessing the predicative
value for survival of colorectal cancer patients remains a
topic that needs to be explored.
Human epidermal growth factor (HER-2/neu), which
encodes a 185-kDa transmembrane tyrosine kinase [2]
and overexpression of HER-2 gene has been found to cor-
relate with poor prognosis in a variety of human cancers,
such as breast, ovarian, and lung cancers [3]. For instance,
overexpression of the HER-2/neu is detectable in 25–35 %
of breast cancers [4]. Treatment of these patients withs distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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antibody, has been shown to reduce tumor volume, mag-
nify the effects of chemotherapy, and increase survival rate
in primary and metastatic breast cancer [5]. However,
there is still a lack of general consensus regarding the
possible prognostic impact of HER-2 in colorectal cancer.
Although a large number of studies were performed on
patients with colorectal cancer, the prognostic value of
HER-2 expression for colorectal cancer patients remains
controversial. We thus conducted this meta-analysis to
indicate the correlation between HER-2 expression and
the clinicopathological characteristics of colorectal cancer
and estimate whether HER-2 can act as a prognostic
marker for patients with colorectal cancer.
Methods
Literature search
Pubmed, Embase and Web of Science were systematically
searched. The search ended in September 1st, 2014, and
no lower date limit was used. Bibliographies cited in an
identified article were also searched manually to triage
other suitable studies. No language restriction was applied,
and we also screened the references of the relevant studies
to check for potentially relevant articles. The search strat-
egy included the following keywords variably combined by
“human epidermal growth factor receptor 2”, “HER-2/
neu”,“c-erbB2”, “colorectal cancer”, “survival” and “prog-
nosis”. Internet search engines were also used to perform
a manual search for abstracts from international meetings,
which were then downloaded and studied.
Inclusion and exclusion criteria
Criteria for eligibility of a study included in this meta-
analysis were: (1) HER-2 expression was measured by
immunohistochemistry, Western blot or fluorescence in
situ hybridization; (2) overall survival rates between differ-
ent expressions of HER-2 in colorectal cancer were com-
pared and (3) hazard ratios (HR) for overall survival rates
according to HER-2 expression were reported or could be
calculated from the data presented. When several studies
were reported from the same authors or organizations,
the meta-analysis enrolled the most recent or highest
quality study only if the most recent one did not fit the in-
clusion criteria. Studies were excluded if (1) Studies were
case reports, letters, and reviews without original data;
animal or laboratory studies; (2) the samples came from
lymph nodes or the peritoneal cavity; (3) the outcomes of
interest were not reported and it was impossible to calcu-
late outcomes from the originally published data or (4)
repeated studies were based on the same database or
patients. To avoid the influence of redundant studies, we
checked all of the authors and organizations, and evalu-
ated the accrual period and community of patients
enrolled for each study.Data extraction
Extracted data were crosschecked between the two
authors (SWW and CCM) to rule out any discrepancy.
Data regarding the following for each included studies
were extracted independently: first authors’ surname, pub-
lication year, sample size, HER-2 assessment methods, the
cut-off definition, clinicopathological characteristics, and
data of HER-2 overexpression for the disease-specific or
overall survival. For the survival analysis, the HR, which
takes into account the number and timing of events, is the
most appropriate statistic to analyze time-to-event out-
comes [6]. For each study the HR and its 95 % confidence
intervals (CIs) were estimated depending upon the data
provided in the literature. In some studies, the HR could
be obtained directly from publications, or could be calcu-
lated by using the O-E statistic and variance in the manu-
script, and unadjusted HRs were considered preferable to
multivariable adjusted HRs in these cases. If a directly
reported HR was not available, HR estimates were calcu-
lated from the data including the number of patients at
risk in each group, the total number of events and the log-
rank statistic or its p value. Otherwise, we extracted
survival rates at specified times from Kaplan-Meier
survival curves to reconstruct the HR estimate according
to previously described methods [7], with the assumption
that patients were censored at an unchanged rate during
the follow-up. Disagreements were discussed by the au-
thors and resolved by consensus.
Statistical analysis
The statistical analysis was carried out using the Review
Manager 5.1. HR was used in this time-to-event analysis,
which takes into consideration the number and timing of
events. The disease-specific or overall survival value of
each study was determined by the combination of HR and
its corresponding 95 % CI. All data were directly obtained
or indirectly computed using the formula recommended
by Tierney [7]. The significance of the pooled HR was
determined by Z test, and P ≤ 0.05 was considered statisti-
cally significant. Pooled HR was calculated using a fixed-
effects model or random-effects model to evaluate the
relationship between HER-2 overexpression and the
disease-specific or overall survival. I2 statistics was used to
evaluate the between-study heterogeneity analysis in this
meta-analysis [8]. The random-effects model was used
when an obvious heterogeneity was observed among the
included studies (I2 > 50 %). The fixed effects model was
used when there was no significant heterogeneity between
the included studies (I2 ≤ 50 %). Meta-regression analysis
by stratifying on study location, publication year, number
of patients, quality score and cut-off value were con-
ducted. For the pooled analysis of the correlation between
HER-2 overexpression and clinicopathological features
(sex, tumor location, TNM stage, grade of differentiation,
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were combined to estimate the effect. An observed HR or
OR > 1 implied a worse prognosis for the group with
HER-2 overexpression and would be considered to be sta-
tistically significant if the 95 % CI did not overlap. Publica-
tion bias was estimated using a funnel plot with a Begg’s
test; funnel plot asymmetry on the natural logarithm scale
of the HR was measured by a line arregression approach.
Results
Study selection and characteristics
A total of 156 articles were identified from a search of the
above databases using the search strategy as described
above. After exclusion of the trials that were out of the
scope of our meta-analysis, 32 studies assessing prognostic
value for survival of HER-2 status in patients with colorec-
tal cancer were considered eligible for inclusion in the
evaluation. Upon further review, 9 were excluded because
it was not possible to allow for the calculation of HR
estimate because of insufficient reported data, 5 were
excluded because they have overlapped data with other
studies. Finally, a total of 18 publications [9–26] were
enrolled for the present meta-analysis (Fig. 1).
The clinical characteristics of these 18 included studies
eligible for the meta-analysis are summarized in Table 1.
Three study assessed the patients from China, three from
Korea, two from Japan, one from Germany, one fromFig. 1 Flow diagram of studies selection procedureEgypt, one from Switzerland, two from Brazil, one from
Ireland, two from Greece, one from USA and one from
UK. The total number of patients included was 2867,
ranging from 44 to 355 patients per study. All of the
included studies used IHC to determine HER-2 status. In
each study, the IHC cut-off values of HER-2 appeared to
be different. These eligible studies were published from
1995 to 2014.
HER-2 overexpression and OS in patients with CRC
Data of overall survival extracted from 16 eligible studies
were included in the meta-analysis. Since the heterogeneity
among those studies for HER-2 expression was insignificant
(I2 = 0 %), a fixed-effect model was used to calculate the
pooled HR with corresponding 95 % CI of OS in CRC
patients. Meta-analysis found that there was no detect-
able relation between HER-2 expression and prognosis
in CRC patients with the pooled HR of 1.08 (95 % CI:
0.96–1.21, P = 0.21) (Fig. 2).
HER-2 overexpression and clinicopathological parameters
in patients with CRC
Twelve studies provided the information of clinicopatho-
logical parameters and their correlation with HER-2 posi-
tive expression was summarized in Table 1. Eleven studies
demonstrated that there was no correlation between HER-
2 expression and gender (OR = 0.91, 95 % CI: 0.72–1.15,
Table 1 Characteristics of studies included in the meta-analysis
Study Year Country No. of patients Age (year) Technique Cut-off value No. of HER-2 Positive (%) Follow-up period (month) Outcome
Baiocchi 2009 Brazil 109 NA IHC >10 % Positive (%) 57.4 (median) OS
Chen 2010 China 44 55 (median) IHC 1+ 14 (31.8) 35 (median) OS, CP
Conradi 2013 Germany 264 63 (mean) IHC, S-ISH 2+ 70 (26.5) 48.5 (median) OS
Drecoll 2014 Switzerland 355 66 (median) IHC, FISH 2+ 51 (14.4) 87 (mean) OS
Ishida 2000 Japan 149 61.6 (mean) IHC NA 44 (29.5) NA OS, CP
Ismail 2007 Egypt 104 47.4 (mean) IHC 1+ 10 (9.6) 18 (median) OS, CP
Jesus 2005 Brazil 108 63.1 (mean) IHC >10 % 52 (48.1) 28.1 (mean) OS
Kavanagh 2009 Ireland 132 67.0 (mean) IHC, FISH 2+ 18 (13.6) NA OS
Lazaris 1995 Greece 60 68.75 (mean) IHC >10 % 21 (35) 60 (median) OS, CP
Li 2011 China 317 57.8 (mean) IHC 2+ 49 (15.5) 68.8 (median) OS, CP
Lim 2013 South Korea 95 69 (median) IHC, FISH 2+ 23 (24.2) 22.7 (median) OS, CP
Lu 2012 China 126 NA IHC >25 % 59 (46.8) NA OS, CP
Mckay 2002 UK 248 NA IHC 2+ 203 (81.9) 43 (median) OS, CP
Osako 1998 Japan 146 65.0 (mean) IHC NA 100 (68.5) 55.2 (median) OS, CP
Pappas 2013 Greece 51 70.9 (mean) IHC 2+ 2 (3.9) 18 (median) OS, CP
Park 2007 South Korea 137 62.4 (mean) IHC, FISH 2+ 65 (47.4) 48.5 (median) OS, CP
Rossi 2002 USA 156 75 (median) IHC 1+ 24 (15.4) 46.8 (median) OS
Shin 2014 Korea 266 63 (mean) IHC 2+ 80 (30.1) NA OS, CP












Fig. 2 Meta-analysis of the association between HER-2 overexpression and the overall survival rate for colorectal cancer patients
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controversies also existed on the correlation among tumor
location, differentiation, lymph node metastasis and HER-
2 overexpression in these included studies. Seven studies
evaluated the relationship between HER-2 expression
and tumor location in CRC patients. The pooled OR
was (OR = 1.21, 95 % CI = 0.88–1.65, P = 0.24, Fig. 4),
suggesting that HER-2 overexpression was not associ-
ated with tumor location. In addition, no correlation
was found between the overexpression of HER-2 and
TNM stage (OR = 0.72, 95 % CI = 0.31–1.66, P = 0.44,Fig. 3 Meta-analysis of the association between HER-2 overexpression andFig. 5), grade of differentiation (OR = 1.03, 95 % CI =
0.72–1.47, P = 0.86, Fig. 6). Moreover, the meta-analysis
suggested that HER-2 overexpression was also not cor-
related with lymph node metastasis (OR = 1.90, 95 %
CI = 0.90–4.02, P = 0.09) (Fig. 7).Publication bias
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of studies. The results showed
that no publication bias was detected in all comparisons.sex for colorectal cancer patients
Fig. 4 Meta-analysis of the association between HER-2 overexpression and tumor location for colorectal cancer patients
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comparisons in patients with CRC (Figures not shown).
Discussion
Up to date, clinically approved biomarkers have been
found to guide treatment and predict outcomes in several
solid tumors, and several studies have demonstrated that
HER-2 is a molecular prognostic biomarker of breast can-
cer [3, 4]. However, the clinical value of HER-2 remains
controversial in several solid tumors including colorectal
cancer. In this meta-analysis, we revealed that overexpres-
sion of HER-2 was negatively correlated with the poor
prognosis of CRC patients. In addition, no correlation was
observed between HER-2 expression and clinicopathologi-
cal features including tumor location, grade of differenti-
ation, TNM stages and lymph node metastasis.
The HER-2/neu gene is located on chromosome 17q21
and encodes a 185-kDa transmembrane protein which ex-
hibits tyrosine kinase activity [27]. The HER-2/neu protein
is extensively homologous and related to the epidermal
growth factor receptor (EGFR) [28]. Similar to EGFR, the
HER-2/neu protein is involved in normal cell proliferation
and tissue growth. Originally, it was observed thatFig. 5 Meta-analysis of the association between HER-2 overexpression andtransfection of multiple copies of the HER-2/neu gene
into nonneoplastic human breast cell lines led to increased
production of the HER-2/neu protein as well as malignant
transformation [29]. HER-2/neu has attracted consider-
able attention in breast cancer, where it has been targeted
successfully in the treatment of patients with advanced
disease [30]. As a prognostic marker, HER-2/neu is used
to predict the probable course and outcome of the disease.
As a predictive marker, HER-2/neu is used to forecast the
patient’s therapeutic response to adjuvant chemotherapy
and endocrine therapy and to select patients for anti-
HER-2/neu monoclonal antibody (Herceptin) immuno-
therapy. Favorable clinical results with anti-HER-2/neu
antibodies in breast cancer have led to the analysis of
HER-2/neu expression in other solid tumors. HER-2/neu
amplification and/or overexpression has also been de-
tected in ovarian, lung, gastric, and colon carcinomas.
With regard to colorectal carcinomas, several immunohis-
tochemical (IHC) studies have reported different frequen-
cies of HER-2/neu overexpression, in a wide range from 0
to 30 % [31]. There are, however, conflicting results in
studies of HER-2/neu with regard to its relationship to
prognosis in colorectal cancer patients. Some studies haveTNM stage for colorectal cancer patients
Fig. 6 Meta-analysis of the association between HER-2 overexpression and grade of differentiation for colorectal cancer patients
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sion and advanced stage, decreased survival, or both.
Other studies have failed to find any association with
prognosis whatsoever.
A previously meta-analysis had been performed to
examine the prognostic role in patients with CRC, and the
result was consisted with us [32]. However, our study
showed the following advancements when compared with
previous work. Firstly, our study included larger sample
size than previous one. After their work published, add-
itional seven studies including 1080 patients were pub-
lished [12–14, 17, 19, 23, 26]. In some degree, our results
were more robust and reliable than previous work. Sec-
ondly, various subgroup analyses were done in our ana-
lysis, while in previous studies, they only conducted
subgroup analysis by race. Thirdly, our study provided
more information and gave a comprehensive insight on
the role of HER-2 in the progression of CRC. In Li’s study,
they only investigated the relationship between HER-2
overexpression and OS. However, in our study, we pro-
vided the information not only OS, but also clinicopatho-
logical features. The present study indicated that there
was no detectable relation between HER-2 expression and
sex, tumor location, grade of differentiation, TNM stages,
or lymph node metastasis in CRC. Based on the aboveFig. 7 Meta-analysis of the association between HER-2 overexpression andpoints, we thought our up-to date meta-analysis was
worthwhile and comprehensive.
However, it should be circumspect to make a verdict
of the association with HER-2 overexpression and CRC,
because there are still several issues should be consid-
ered. First, the methods used for the evaluation of the
levels of markers in CRC patients and the use of stand-
ard threshold, are both likely to impact on our results.
In the studies we included, IHC techniques used to
detect protein expression were not the same, including
antibody type and concentration, the cut-off value defin-
ition and none of the included studies mention the
information of interobserver variation. But it is very
important for HER-2 assessing. Moreover, lack of spe-
cific criteria for assessing HER-2 positivity according to
different types of cancer is a situation, which should and
would be improved in the future. These differences
could contribute to the heterogeneity. Second, the small
size of the patient cohorts in included studies led to a
lack of power in identifying the relation between the
proposed prognostic factor and outcome. The studied
populations may not have accurately represented the
lack of abundant HER-2 expression data in global popu-
lation makes it difficult to set a standard value for the
measurement of HER-2 status. Third, in some studies,lymph node metastasis for colorectal cancer patients
Wu et al. Diagnostic Pathology  (2015) 10:144 Page 8 of 9the HRs and their corresponding 95 % CIs were indir-
ectly calculated from other survival data or extracted
from the survival curves, which may bias our results. All
of these factors might partly influence the significance of
HER-2 expression in the survival and the clinicopatho-
logical analysis.
Conclusion
This meta-analysis indicated that overexpression of HER-
2 was not related to the poor survival in CRC patients and
no correlation exists between HER-2 overexpression and
other common clinicopathological parameters such as
tumor location, TNM stage, tumor differentiation and
lymph node metastasis. Therefore, HER-2/neu overex-
pression might not be a significantly progress and prog-
nostic indicator for patients. Well-designed clinical studies
with large cases of CRC should be performed in the future
to validate the relationship between HER-2 overexpression
and prognosis of CRC patients.
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